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Learning from Nature: From a Marine Natural Product to
Synthetic Cyclooxygenase-1 Inhibitors by Automated De
Novo Design
Lukas Friedrich, Gino Cingolani, Ying-Hui Ko, Mariaclara Iaselli, Morena Miciaccia,
Maria Grazia Perrone, Konstantin Neukirch, Veronika Bobinger, Daniel Merk,
Robert Klaus Hofstetter, Oliver Werz, Andreas Koeberle, Antonio Scilimati,
and Gisbert Schneider*
The repertoire of natural products oﬀers tremendous opportunities for
chemical biology and drug discovery. Natural product-inspired synthetic
molecules represent an ecologically and economically sustainable alternative
to the direct utilization of natural products. De novo design with machine
intelligence bridges the gap between the worlds of bioactive natural products
and synthetic molecules. On employing the compound Marinopyrrole A from
marine Streptomyces as a design template, the algorithm constructs
innovative small molecules that can be synthesized in three steps, following
the computationally suggested synthesis route. Computational activity
prediction reveals cyclooxygenase (COX) as a putative target of both
Marinopyrrole A and the de novo designs. The molecular designs are
experimentally conﬁrmed as selective COX-1 inhibitors with nanomolar
potency. X-ray structure analysis reveals the binding of the most selective
compound to COX-1. This molecular design approach provides a blueprint for
natural product-inspired hit and lead identiﬁcation for drug discovery with
machine intelligence.
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1. Introduction
Natural products are an important source
of inspiration for medicinal chemists.
Reportedly, more than one third of all
drugs approved by the U.S. Food and Drug
Administration are natural products or
natural product-inspired drugs.[1] Natural products and their chemical building
blocks are also preferred starting points
for small-molecule drug discovery.[2] However, the biological activity of most natural
products is unknown, and many pharmacologically active natural products are scarce,
precluding their reaping from natural
sources or requiring elaborate synthetic
routes, which renders industrial production unattractive.[3] Consequently, the full
potential of natural products for drug
discovery remains mostly untapped and
unexplored. Herein, we present an eﬃcient
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Figure 1. Natural product-inspired scaﬀold hopping. Chemical structure of (±)-Marinopyrrole A (1, left), which served as the design template, and the
most prominent de novo generated molecular scaﬀold (2,4,5-triphenyl imidazole, Iophine, middle). The structure of the non-steroidal anti-inﬂammatory
drug celecoxib is shown for comparison (right).

computational strategy for target identiﬁcation and de novo design of synthetically accessible natural product mimetics. This
integrated approach combines automated, rule-based molecule
construction with machine learning and experimental validation in a rapid design-make-test-analyze cycle. For experimental
proof of concept, we selected marine natural product Marinopyrrole A (compound 1, Figure 1) as the design template for
the automated generation of new molecules.[4] This compound
possesses not only anti-bacterial properties but also potent anticancer activity.[5,6] The shortest known total synthetic route
aﬀorded (±)-Marinopyrrole A in ﬁve steps and 16% overall
yield.[7] Thus, the primary design goal was to computationally
obtain novel, more easily synthesizable druglike molecules that
share disease-relevant macromolecular targets with Marinopyrrole A.
In addition to obtaining novel natural product-inspired synthetic compounds, in this study, we aimed to analyze the degree to which the bioactivities of the design template are transferred to the de novo generated molecules. These designs should
be (iso)functional rather than structural mimetics of the natural product template (“new structure, same function”). For
computational structure generation, the DOGS (design of genuine structures) de novo design algorithm was utilized.[8] The
CATS (chemically advanced template search) distance metric
was employed for ranking the computer-generated molecules.[9]
The DOGS method constructs new molecules by combining
molecular building blocks according to a list of in silico chemical transformations.[10] Importantly, this molecular design algorithm is solely guided by the molecular similarity between the
template and virtual molecules and does not rely on activity prediction for molecule construction and selection. In contrast to
rule-free generative machine learning models,[11,12] the algorithm
generates molecules in a forward-synthetic fashion and is thus
able to suggest synthetic routes for the designs. The results of
this study suggest that this approach may serve as a prototype for
sustainable, natural product-inspired hit and lead identiﬁcation
in chemical biology and drug discovery.

set of 25 563 commercially available building blocks and 58
reaction schemes.[13] The enormous number of potential reaction products does not permit exhaustive enumeration of all
possible virtual products. Therefore, the DOGS algorithm performed a deterministic breadth-ﬁrst search among the virtually
constructed molecules that require no more than three linear
synthesis steps. Otherwise, the structure generation process
was unconstrained. The pairwise molecular graph similarity
between generated molecules and the Marinopyrrole A template
(compound 1) served as the ﬁtness function during the molecule
construction process.[14] This permissive (“fuzzy”) similarity
criterion was previously shown to enable molecular scaﬀold
hopping between the design template and generated molecules,
identifying pairs of structurally dissimilar yet functionally related compounds.[15,16,17] Other than the chemical constitution of
Marinopyrrole A, no other information (e.g., 3D conformation,
target information) was used in the molecular design process.
For the Marinopyrrole A template, the DOGS algorithm
generated a total of 802 de novo designs, comprising 334 unique
molecular scaﬀolds (Figure S1, Supporting Information).[18]
The designs were ranked according to their topological pharmacophore similarity to Marinopyrrole A (CATS distance metric;
lower distance values indicate more similar compounds in terms
of the CATS molecular representation).[9] The 100 top-ranking
designs presented CATS distances < 1.8 (Table S1, Supporting
Information), suggesting a balanced compromise between
conservative (small distance) and explorative (large distance)
scaﬀold variations. This set of molecules contained 38 unique
scaﬀolds, among which 2,4,5-triphenyl imidazole (lophine)[19]
was the most frequent (34%, 15% of all 802 generated molecules,
Figure 1; Figure S2, Supporting Information). Among designs
containing this scaﬀold (Figure S3, Supporting Information),
compounds 2 (best ranking, CATS distance = 1.45) and 3 (CATS
distance = 1.70) were selected for synthesis. For these two de
novo designs, the DOGS algorithm suggested strikingly similar
synthetic routes (Figure 2a).

2. Results

2.2. Synthesizing the Molecules

2.1. Designing the Molecules

The computationally proposed synthetic procedures involve imidazole formation from a dicarbonyl compound, an aldehyde, and
ammonia, known as the Debus–Radziszewski reaction.[20] To obtain compound 2 from intermediate product 4 of this reaction,

New molecules were constructed with DOGS software from
200 randomly selected starting fragments, with a construction

Adv. Sci. 2021, 8, 2100832

2100832 (2 of 12)

© 2021 The Authors. Advanced Science published by Wiley-VCH GmbH

www.advancedsciencenews.com

www.advancedscience.com

Figure 2. Synthetic routes to de novo designs 2 and 3. Molecule construction, as suggested by a) the molecular design algorithm and b) the actual
chemical synthesis. Both routes consist of an imidazole formation via Debus–Radziszewski reaction. To synthesize compound 2 from the imidazole
intermediate 4, esteriﬁcation of the phenol group with 2-hydroxyacetyl chloride was proposed by the software. b) Chemical synthesis of compounds 2,
2a, 2b, and 3. Reagents and conditions: i) NH4 OAc, AcOH, reﬂux, 5 h, 66%; ii) (I) TBDPS-protected glycolic acid, DCC, DMAP, CH2 Cl2 , RT, 16 h, 38%;
iii) TBAF, AcOH, THF, 0 °C to RT, 2 h, 82% (2); iv) 2-methoxyacetic acid or acetic acid, DCC, DMAP, CH2 Cl2 , RT, 16 h, 57% (2a), 53% (2b); iv) NH4 OAc,
AcOH, µw irradiation, 180 °C, 5 min, 48%.

the DOGS software proposed esteriﬁcation of the phenol with an
acyl halide. Imidazole synthesis was conducted for compounds 4
and 3 as proposed by the software in moderate yields (66% and
48%, respectively). Cyclization of compound 4 was successful under conventional oil bath heating, whereas compound 3 was prepared under microwave irradiation in a sealed vial. To prevent
the self-reaction of glycoloyl chloride in the computationally proposed esteriﬁcation approach, this second synthetic step for compound 2 was achieved by Steglich esteriﬁcation[21] using N,N′dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine

Adv. Sci. 2021, 8, 2100832

(DMAP) as a nucleophilic catalyst, and silyl protection of glycolic
acid, followed by desilylation with tetrabutylammonium ﬂuoride
(TBAF) (Figure 2b). Derivatives 2a and 2b were synthesized using
the same synthetic strategy.

2.3. Testing the Biological Activity of the Designs
To identify macromolecular targets of the template Marinopyrrole A and its computationally designed mimetics, we employed
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Table 1. Eﬀect of Marinopyrrole A (1) and mimetic compounds 2, 2a, 2b, 3, and 4 on isolated bovine cyclooxygenase (COX)-1, human recombinant
COX-2, and COX-1 activity in human platelets.
COX-1 (enzyme)
Compound

Residual activity / [%]

1

7.7 ± 3.9a *

2

1.5 ± 0.4a ***

COX-2 (enzyme)
IC50 / [µm]

Residual activity / [%]

IC50 / [µm]

COX-1 (platelets)
IC50 / [µm]

16.6 ± 2.3

41.6 ± 2.8a *

45.2 ± 21.3

18.7 ± 1.1

0.101 ± 0.051

26.6 ± 4.8a *

11.8 ± 5.5

0.009 ± 0.000

2a

21.6 ± 6.3a **

0.160 ± 0.001

99.2 ± 27.2a

n.d.

0.013 ± 0.005

2b

71.0 ± 2.6b *

n.d. (>100)

92.4 ± 23.5b

n.d.

0.056 ± 0.015

3

22.9 ± 8.5a *

29.7 ± 18.1

27.5 ± 13.8a *

62.4 ± 16.8

1.9 ± 0.1

4

17.5 ± 5.6a *

2.1 ± 0.3

34.0 ± 3.2a

46.6 ± 10.6

1.9 ± 0.4

Indomethacin

28.5 ± 3.5b ***

2.8 ± 0.3

34.7 ± 5.2b ***

10.6 ± 6.6

0.008 ± 0.002

a,b Residual

activities (% of control) at 100 or 10 µM compound concentration, respectively; IC50 values are given as mean ± SEM of single determinations obtained in three
or six (indomethacin) independent experiments; *p < 0.05, **p < 0.01, ***p < 0.001; paired student t-test; n.d., not determined; IC50 , half maximal inhibitory concentration.

SPiDER (self-organizing map-based prediction of drug equivalence relationships) target prediction software.[22] The SPiDER
algorithm infers the potential biological targets of a given query
molecule from comparisons with local ensembles of similar compounds and known bioactivities. This is achieved by two cascaded
machine learning models (self-organizing maps), considering
the molecular similarity in terms of physicochemical properties
and molecular pharmacophore features, respectively.[23] In previous studies, SPiDER was successfully applied to predict targets
of natural products and small molecules.[24,25,26] Predictions with
p ≤ 0.05 were considered meaningful. Marinopyrrole A received
the fewest target predictions (n = 8), with compound 3 demonstrating the highest number of predictions (n = 43). Furthermore,
seven of the eight computed targets of Marinopyrrole A were additionally suggested for all of the mimetics (prostanoid receptors,
cannabinoid receptors, peroxisome proliferator-activated receptors (PPAR), corticotropin-releasing hormone receptors (CRF),
cyclooxygenases (COXs), serine/threonine protein kinases, and
glucagon receptor; Table S2, Supporting Information).
In a preliminary screen, the compounds were tested at a
concentration of 50 µm to determine activity toward selected
members of the predicted target families. Compounds 2 (IC50 =
1.2 ± 1.2 µm, KB = 0.6 µm), 3 (IC50 = 4.3 ± 1.2 µm, KB = 2.2 µm),
and 4 (IC50 = 1.4 ± 1.1 µm, KB = 0.7 µm) demonstrated an
antagonistic eﬀect on the glucocorticoid receptor (Figure S4,
Supporting Information). Compounds 3 (IC50 = 4.7 ± 1.2 µm,
Ki = 1.7 µm), and 4 (IC50 = 40 ± 2 µm, Ki = 14 µm) showed
antagonistic eﬀects toward CRF1. Compound 3 additionally antagonized orexin receptor 1 (IC50 = 40 ± 1 µm, Ki = 8.4 µm) and
cholecystokinin B receptor 2 (IC50 = 8.7 ± 4.6 µm, Ki = 1.1 µm).
Marinopyrrole A and mimetics 2, 2a, and 4 were further investigated for their interaction with PPAR and a panel of related
nuclear receptors in reporter gene assays (Figure S5, Supporting
Information). Only Marinopyrrole A showed activity in these assays, namely the natural product activated PPAR𝛿 (EC50 = 0.9 ±
1.2 µm), as predicted, as well as retinoic acid receptor 𝛼 (EC50 =
0.6 ± 0.1 µm), vitamin D receptor (EC50 = 1.1 ± 0.1 µm), and
liver X receptor 𝛽 (EC50 = 0.3 ± 0.4 µm) (Figure S6, Supporting
Information). The human glucocorticoid receptor, and orexin
receptors 1 and 2 were additionally conﬁrmed as known targets
of Marinopyrrole A (Table S3, Supporting Information).

Adv. Sci. 2021, 8, 2100832

The preliminary assay results indicated pronounced COX-1inhibitory activity of the compounds. COX-1 was not known as
a target of Marinopyrrole A. Evidently, the computer-generated
molecules inherited this activity from the natural product
template. Therefore, the compounds were further investigated
using cell-free assays (Table 1; Figures S7 and S8, Supporting
Information). Concordant results were obtained independently
of whether the COX product 12(S)-hydroxy-5-cis-8,10-transheptadecatrienoic acid (12-HHT) was analyzed, or the enzyme’s
endoperoxidase activity was measured (Figure S9, Supporting Information). Marinopyrrole A inhibited COX-1 in the
double-digit micromolar range (IC50 = 16.6 ± 2.3 µm), whereas
compounds 2, 2a, and 4 were conﬁrmed to demonstrate potent
COX-1 inhibition with nanomolar (2, IC50 = 0.10 ± 0.05 µm;
2a, IC50 = 0.160 ± 0.001 µm) or micromolar (4, IC50 = 2.1 ±
0.3 µm) activity (Table 1). However, inhibition of COX-2 was
instead only evident at high concentrations of Marinopyrrole
A (IC50 = 45 ± 21 µm) and its synthetic mimetics (2, IC50 =
12 ± 6 µm, 2a, IC50 > 100 µm; 4, IC50 = 47 ± 11 µm; Table 1).
At the time of this study, there were 7911 COX-1 and 9648
COX-2 inhibitors in the ChEMBL24 database,[27] of which only
seven compounds, annotated as “selective COX-2 inhibitors”,[28]
contained the 2,4,5-triphenyl imidazole scaﬀold similar to the
de novo designs, although with diﬀerent substitution patterns
and the non-steroidal anti-inﬂammatory drug (NSAID) celecoxib
present among them (Figure 1).
COX-1 dominates prostanoid formation in monocytes and
platelets, with the latter exclusively expressing COX-1 but not
COX-2. Both compound 2 (IC50 = 0.009 ± 0.000 µm) and its
analogs 2a (IC50 = 0.013 ± 0.005 µm) and 2b (IC50 = 0.056 ±
0.015 µm) showed pronounced COX-inhibitory activity in human platelets (Table 1; Figure S9, Supporting Information)
and monocytes (Figure 3; Figure S10, Supporting Information;
prostaglandin E2 : 2, IC50 < 0.01 µm). COX-1 inhibition in
platelets by compound 2 (IC50 = 0.009 ± 0.000 µm) may be considered equipotent to indomethacin (IC50 = 0.008 ± 0.002 µm)
(Table 1; Figures S8 and S10, Supporting Information). The
compounds with free phenolic alcohol, Marinopyrrole A (1), and
compound 4 were comparably eﬀective in platelets and against
isolated COX-1 (Table 1). The capacity of monocytes to produce
prostaglandin E2 strongly increased when COX-2 expression was
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Figure 3. Compound 2 preferentially inhibits COX-1 product formation in human monocytes. Monocytes were directly treated with vehicle (DMSO) or
compound 2 (“w/o LPS”) or ﬁrst activated with LPS to induce COX-2 expression (“with LPS“). Then, monocytes were activated with A23187, and lipid
mediator proﬁles were analyzed by UPLC-MS/MS. a) Quantitative illustration of the arachidonic acid (AA)-derived lipid mediator network of monocytes
treated with compound 2 (0.01 µm) compared with vehicle control. The node size represents the average concentration in picograms (pg), and the
color intensity denotes the fold change for each lipid mediator from n = 3 independent experiments. b) Comparison of the inhibition of COX product
formation by compound 2 in A23187-treated monocytes with and without pre-treatment with LPS. Mean ± SEM from n = 3 independent experiments
as a percentage of vehicle control. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control; repeated measures two-way ANOVA + Tukey’s post hoc
test of logarithmized data. AA, arachidonic acid; (di)HETE, (di)hydroxy-eicosatetraenoic acid; LT, leukotriene; t-LTB4 , trans-LTB4 isomers; 20-OH-LTB4 ,
20-hydroxy-LTB4 ; LX, lipoxin; PG, prostaglandin E2 , D2 , F2𝛼 ; TXB2, thromboxane B2; 12-HHT, 12-hydroxyheptadecatrenoic acid; COX, cyclooxygenase;
DMSO, dimethyl sulfoxide; UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry.

induced by lipopolysaccharide (LPS) treatment, while the potency of compound 2 (IC50 = 0.065 µm) to inhibit prostaglandin
E2 formation decreased (Figure 3; Figure S11, Supporting Information), as expected from the superior inhibition of COX-1 over
COX-2.
The eﬀect of compound 2 on the monocyte lipid mediator
network was investigated by targeted metabololipidomics using
ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Compound 2 inhibited the biosynthesis of the COX-derived prostanoids prostaglandin E2 , D2 ,
F2𝛼 , and thromboxane B2 , but did not substantially suppress 5lipoxygenase, 12-lipoxygenase, and 15-lipoxygenase product formation or fatty acid release by phospholipase A2 (Figure 3a,b). In
monocytes pretreated with LPS, compound 2 redirected the fatty
acid substrates to the 5-lipoxygenase pathway (Figure 3), a common feature of COX inhibitors.[29] Overall, the de novo designed
Marinopyrrole A mimetic 2 is a potent inhibitor of COX-1, which
preferentially inhibits the biosynthesis of COX-1-derived products in human platelets and monocytes.

Adv. Sci. 2021, 8, 2100832

2.4. Analyzing the Molecular Mechanism of COX-1 Inhibition
The obtained bioactivity data suggested that compound 2 inhibits
COX-1 independently of the arachidonic acid concentration (Figure 4a) in a pseudo-irreversible manner (Figure 4b). To determine
the binding mode and rationalize these biochemical eﬀects, we
determined the crystal structure of the ovine COX-1 (oCOX-1)
in complex with the subtype-selective derivative 2a (oCOX-1
IC50 = 0.160 ± 0.001 µm, inactive on hCOX-2, Table 1). The
complex was solved by molecular replacement and reﬁned to a
Rwork/free of 20.97/24.99% at 3.35 Å (Figure 5a; Table S4, Supporting Information, PDB-ID: 7JXT). The overall architecture of
the enzyme in this crystallographic complex was similar to previously reported structures.[30] COX-1 crystallizes as a homodimer in the asymmetric unit, consisting of two ≈72 kDa subunits
tightly packed against each other via an extensive binding interface of ≈2500 Å2 . Compound 2a was identiﬁed in an unbiased
Fo–Fc polder map within the oCOX-1 hydrophobic channel between residues Arg120 and Tyr355 (Figure 5b).[31,32] The Fo–Fc
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Figure 4. Compound 2 inhibits COX-1 independent of the substrate concentration and kills human cancer cells. a) Eﬀect of the substrate concentration
(arachidonic acid, AA) on the inhibition of isolated COX-1 by compound 2. b) Reversibility of COX-1 inhibition by compound 2. Samples were preincubated with vehicle or compound 2 for 5 min, tenfold diluted in assay buﬀer, and incubated for 10 min before arachidonic acid was added. Numbers
in brackets indicate the diluted compound concentration after pre-incubation. a,b) 12-HHT was analyzed by UV-RP-HPLC. Mean ± SEM from n =
3 independent experiments as a percentage of vehicle control. **p < 0.01, ***p < 0.001 versus 20 µm arachidonic acid (a) or vehicle (b); repeated
measures two-way (a) or one-way ANOVA (b) + Tukey’s post hoc test. c) Eﬀect of compound 2 on human cancer cell lines, as determined in a cell
viability MTT assay. MCF-7, Michigan Cancer Foundation-7 breast cancer cells; MIA PaCa-2, pancreatic cancer cells; Caco-2, colon cancer cells; Hep-G2,
liver cancer cells; A-549, adenocarcinoma alveolar basal epithelial cells; PANC-1, pancreatic cancer cells; 12-HHT, 12-hydroxyheptadecatrenoic acid; COX,
cyclooxygenase; UV-RP-HPLC, ultraviolet-reverse phase high-performance liquid chromatography.

density map for compound 2a presented clear density features
at 3.2 𝜎 above background, which allowed the unambiguous assignment of the ligand orientation. The methoxyacetate residue
of compound 2a was the only part of the molecule that did not
have a clear density in the crystal structure (left panel of Figure 5b), possibly underscoring its ﬂexibility and lack of binding
interactions. For compound 2a, a side view of density revealed a
ﬂat shape consistent with two planar chlorobenzenes (right panel
of Figure 5b).
The crystal structure revealed that the inhibitor resided in
the active site of the enzyme in an almost planar conformation. Compound 2a bound to the substrate channel with one
chlorobenzene facing Ser530, and another chlorobenzene facing down near residues Tyr355 and Arg120, the entry point to
the active site. The ligand was engaged in two sets of interactions with oCOX-1 residues, namely a hydrogen bridge between
a chlorine atom of the ligand and the hydroxyl group of residue
Ser530, and multiple non-bonded van der Waals and hydrophobic contacts with 19 oCOX-1 residues. The ligand portion in the
distal binding pocket was surrounded by hydrophobic residues
(Leu531, Leu534, Leu535, Ile345, Met113) and formed van der
Waals interactions with Lys360. Furthermore, the two chlorobenzene rings were surrounded by several hydrophobic residues
(Ile523, Leu352, Met522, Tyr387), suggesting van der Waals interactions with Ser353. The binding free energy of compound
2a for oCOX-1 was calculated from atomic coordinates as ΔG =
−4.1 kcal mol−1 .

3. Discussion
Ligand-based de novo molecular design was successfully combined with a machine learning model for target prediction.
The rule-based machine intelligence autonomously constructed
molecules using a linear virtual synthesis approach that could be

Adv. Sci. 2021, 8, 2100832

realized in practice. Notably, Marinopyrrole A received considerably fewer target predictions than the computationally generated mimetics, suggesting multiple bioactivities and greater target promiscuity of the synthetic derivatives, which is consistent
with its unique chemical structure and the concept of privileged
scaﬀolds in natural products.[33] Of the eight top-ranking predicted target families, the computer-generated molecules were
conﬁrmed to inherit at least three targets (COX-1, prostaglandin
receptors EP1–EP3, and CRF; Table S3, Supporting Information).
This result corroborates the suitability of ligand-based similarity metrics for molecular de novo design,[25,34] and further validates the CATS topological pharmacophore metric as suitable
for compound prioritization and scaﬀold hopping from natural products.[35] During the study, no information regarding the
macromolecular targets was used in the design or selection of the
new compounds. The chemical constitution of the natural product Marinopyrrole A served as the only reference information for
automated ligand-based fragment assembly. This computational
approach might, therefore, prove particularly useful in low-data
situations that are restrictive for de novo drug design with generative deep learning, thereby complementing so-called “one-shot”
methods.[36] Indeed, the concept of this rule-based compound
construction strategy perfectly complements data-hungry deep
learning methods. Furthermore, it is based on established chemical transformations that can be applied without the requirement
for training data, thereby mimicking a chemist’s approach to
drug design.
This strategy not only succeeded in identifying a COX-1 inhibitor but also yielded compounds that are markedly potent
and highly selective over COX-2 and other enzymes involved in
lipid mediator biosynthesis, as veriﬁed in innate immune cells by
metabololipidomics. COX inhibitors are among the most prominent categories of compounds in the drug market and are categorized into the class of traditional NSAIDs that inhibit both COX-1
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Figure 5. Crystallographic analysis of compound 2a bound to oCOX-1. a) Cartoon representation oCOX-1 homodimer with the two chains colored in grey
and blue, and inhibitor 2a colored in magenta. b) Fo–Fc polder map for compound 2a contoured at 3.2 𝜎 above background. The map was calculated
using all reﬂections between 15 and 3.35 Å resolution. The reﬁned atomic model of compound 2a is overlaid to electron density (mesh). c) Structural
determinants for compound 2a binding to the oCOX-1 active site, with residue side chains lining the oCOX-1 active site within 2.5–4.0 Å distance from
compound 2a. The hydrogen bridge (length = 2.9 Å) formed between catalytic Ser530 and compound 2a is shown as a dashed line. Arg120 and Tyr355
ﬂank the substrate entry point (black arrow) to the active site. d) Schematic of aligned COX-1 inhibitors 2a, (deep purple, PDB-ID: 7JXT), indomethacin
(orange, PDB-ID: 2OYU), and celecoxib (green, PDB-ID: 3KK6). Two opposite ligand binding pockets are indicated by dashed lines. Images and the
alignment were prepared using PyMol software (Schrödinger, New York, NY, USA). oCOX-1, ovine cyclooxygenase-1.

and COX-2, as well as into the class of COX-2-speciﬁc inhibitors,
referred to as coxibs.[37] For example, both indomethacin and diclofenac may be considered nonselective COX inhibitors with a
slight preference for COX-1 (Table 1, IC50 oCOX-1/hCOX-2 =
0.26; 0.16[38] ), whereas celecoxib is a COX-2-selective inhibitor
(IC50 oCOX-1/hCOX-2 = 600[38] ). There are only a few known selective COX-1 inhibitors.[39] Compounds 2 and 2a demonstrated
comparable activity to other COX-1-selective inhibitors, including SC-560 (IC50 = 9 nm)[40] or FR122047 (IC50 = 28 nm);[41] however, in contrast to these known inhibitors, they presented both
selectivity and pronounced activity in intact cells and platelets,
respectively. Compound 2 behaved similar to indomethacin with
regard to COX-1 inhibition in platelets and showed greater COX1 selectivity (Table 1, IC50 oCOX-1/hCOX-2 = 0.009). It remains
to be determined whether this potential advantage as NSAIDs
also translates to an anti-proliferative anticancer eﬀect, which has
been reported for other selective COX-1 inhibitors.[42] Similar to
the natural product template, designed compound 2 was active
against several human cancer cell lines (Figure 4c). In light of
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these new ﬁndings, the apoptosis regulator Mcl1-independent
anticancer activity of Marinopyrrole A could be reexamined.[43]
Except for aspirin, which covalently and irreversibly inhibits
COX by acetylation of the enzymes at Ser530, all other NSAIDs
bind noncovalently as either (i) rapid and time-dependent arachidonic acid-competitive inhibitors or (ii) time-independent tight
inhibitors that slowly form very stable complexes with COX and
are highly potent.[44] Compound 2a inhibited COX-1 independently of the arachidonic acid concentration in a highly potent
manner, which was conﬁrmed in wash-out experiments indicating tight binding (Figure 4b). Previous studies have revealed
that small-molecule NSAIDs interact with the proximal and central inhibitor binding side of COX, which both overlap with the
binding pocket for arachidonic acid.[45] The majority of these
drugs inhibit both COX isoforms, although with varying degrees
of selectivity. In the COX-2 subtype, substitutions of Ile434Val,
His513Arg, and Ile523Val in the substrate channel constitute
the only diﬀerences between COX-2 residues and COX-1.[46]
Therefore, the design of COX-2 selective inhibitors is focused on
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optimizing interactions with Arg513 at the bottom of the proximal binding pocket of the enzyme.[47] This structural preference
is visible in the alignment of de novo designed COX-1 selective
compound 2a with celecoxib (Figure 5d). However, the binding
pose of inhibitor 2a markedly diﬀered from the COX-1 binding mode of NSAIDs such as indomethacin (PDB-ID: 2OYU)[48]
and celecoxib (PDB-ID: 3KK6)[49] (Figure 5d). Unlike these inhibitors, compound 2a was bound to the distal binding pocket
of the active site. All three compounds interacted with the catalytic Ser530 and structurally overlapped in this central part,
whereas compound 2a adopted an inverted orientation, occupying a hydrophobic protein pocket lined by residues Met113,
Val116, Ile345, Lys360, Leu531, Leu534, and Leu535 (Figure 5c).
This binding pose mimics the bound state of the endogenous
substrate arachidonic acid.[50] Importantly, the molecular frameworks of the de novo molecules and COX-2 inhibitors such as
celecoxib feature the 2,4,5-triphenyl imidazole scaﬀold. The main
diﬀerence lies in their respective substitution patterns (Figure 1).
Moreover, it should be noted that the automated molecular design process generated the same generic scaﬀold found in known
synthetic COX-2 inhibitors by employing only the structurally unrelated natural product Marinopyrrole A as a design template.
The 4,5-biphenyl portion of the selected lophine scaﬀold represents a preferred solution of the “chemical machine intelligence”.
This substructure motif is conserved among the top-ranking designs. These new molecules presented here might open up new
possibilities for developing COX inhibitors.
According to the World Health Organization, the global population relies on natural products for the treatment of diseases.[51]
However, these natural resources are endangered and limited,
and for many pharmacologically active natural products, the
mode of action remains elusive. Converting the often intricate
chemical structures of these natural products into synthetically
more easily accessible drugs is a continuing challenge. The
straightforward molecular design approach presented here combined machine learning models for chemical structure generation (DOGS), ranking (CATS), and target prediction (SPiDER)
for rapid access to natural-product-inspired synthetic compounds
and suggested synthetic routes. Each of these software modules can be replaced with alternative solutions.[52] For example, on losing the forward-synthetic concept, generative “long
short-term memory networks” were successfully employed as
an alternative to the rule-based DOGS algorithm for the constructive natural-product-inspired design of novel nuclear hormone receptor modulators.[53] Furthermore, the software modules for molecule construction and bioactivity prediction may
be combined using, for example, reinforcement or transfer
learning.[54,55] Owing to the limited number of prospective applications, which is, in part, due to limited data availability for deep
learning in drug design, any judgment on the superiority of a
method may be premature. Partial predictability is a fundamental
challenge for rational drug discovery.[16,56,57] Learning from natural products with machine intelligence may oﬀer a path forward.

4. Experimental Section
Computational: Prediction of potential macromolecular targets was
performed with SPiDER[26] software implemented as a KNIME node (version 3.2.1, KNIME, Konstanz, Germany). Molecular scaﬀolds and frame-
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works were extracted with DataWarrior (version 4.7.2, Idorsia Pharmaceuticals, Switzerland). Substructure searching with the 2,4,5-triphenyl imidazole scaﬀold query was performed in ChEMBL24 (2275906 compounds,
accessed 12/14/2018).[28]
Chemical Synthesis and Analytics: All chemicals were purchased in
highest available purity. Reagents and solvents were used without further puriﬁcation unless described otherwise. All reactions were performed
in oven-dried glassware (110 °C), in absolute solvents, and under inert
atmosphere (nitrogen or argon atmosphere). Microwave reactions were
carried out in a Biotage Initiator 2.5 reactor. IR spectra were recorded in
ethanol on a PerkinElmer Spectrum 100 FTIR spectrometer (PerkinElmer,
Waltham, MA, USA), over a scan range of 600–4000 cm−1 . UV/vis spectra were recorded in ethanol on an Agilent Cary-60 UV/vis spectrometer
(Agilent, Santa Clara, CA, USA), over a scan range of 200–800 nm. NMR
spectra were recorded on a Bruker AV 400 or Bruker AV 500 spectrometer (Bruker Corporation, Billerica, MA, USA). Chemical shifts (𝛿) were reported in ppm relative to tetramethylsilane (TMS) reference and coupling
constants (J) were reported in Hertz (Hz). High-resolution mass spectra
(HRMS) were recorded on a Bruker maXis – ESI-Qq-TOF-MS (Bruker Corporation, Billerica, MA, USA). Melting points (mp) were measured on a
Büchi Melting Point M 560 (Büchi, Essen, Germany). Purity of all compounds was determined by reverse phase HPLC-MS with UV and ESI-MS
detection on a Shimadzu (Kyoto, Japan) LC-MS 2020 system with a Nucleodur C18 HTec column (150 × 3 mm, 5 µm, 110 Å) and a linear 50–95%
or 30–95% acetonitrile in water (MilliQ) gradient containing 0.1% formic
acid over 16 min with a ﬂow rate of 0.5 mL min−1 at 40 °C. All compounds
for biological testing had a purity >95% (area under the curve for UV250
peaks).
2-Allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2-yl)phenol
(4): 1,2bis(2-Chlorophenyl)ethane-1,2-dione (5, 0.52 g, 1.8 mmol, 1.0 equiv.),
3-allyl-2-hydroxybenzaldehyde (6, 0.30 g, 1.8 mmol, 1.0 equiv.), and
ammonium acetate (1.5 g, 18 mmol, 10 equiv.) were dissolved in glacial
acetic acid (10 mL) and heated for 5 min to 180 °C under microwave
irradiation. After cooling to room temperature, the mixture was added
dropwise to a cold ammonium hydroxide solution (25%, 150 mL). A yellow
precipitate was ﬁltered oﬀ and washed with cold water. The crude product
was then puriﬁed by column chromatography using hexane/CH2 Cl2 (6:1
+ 5% MeOH) to CH2 Cl2 with 5% MeOH as mobile phase to yield the
title compound as colorless solid (210 mg, 27%). mp = 70 °C; 1 H-NMR
(400 MHz, DMSO-d6 ): 𝛿 = 13.28 (s, 1H, NH), 13.09 (s, 1H, OH), 7.85
(dd, J = 7.9, 1.6 Hz, 1H, CHar ), 7.60–7.52 (m, 1H, CHar ), 7.51–7.25
(m, 7H, CHar ), 7.15 (dd, J = 7.4, 1.4 Hz, 1H, CHar ), 6.90 (t, J = 7.6 Hz,
1H, CHar ), 6.01 (ddt, J = 16.7, 10.1, 6.6 Hz, 1H, CH2 ═CH), 5.12–5.00
(m, 2H, CH═CH2 ), 3.48–3.36 (m, 2H, Car CH2 ); 13 C-NMR (101 MHz,
DMSO-d6 ): 𝛿 = 154.5, 145.1, 136.7, 134.0, 133.2, 132.5, 132.3, 131.6,
130.6, 130.3, 129.9, 129.8, 129.4, 129.3, 127.4, 127.3, 127.0, 126.1, 122.8,
119.5, 118.6, 115.6, 112.3, 33.6; HRMS (ESI): m/z 421.0869 calculated for
C23 H19 Cl2 N2 O2 + ([M+H]+ ), found 421.0871.
2-Allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2-yl)phenyl
2hydroxyacetate (2): 2-((tert-Butyldiphenylsilyl)oxy)acetic acid (0.13 g,
0.41 mmol, 1.2 equiv.) was dissolved in CH2 Cl2 (2 mL). 4(Dimethylamino)pyridine (6.2 mg, 0.050 mmol, 0.14 equiv.) and 4
(0.15 g, 0.36 mmol, 1.0 equiv.) were added and the mixture was cooled
to 0 °C. After 15 min, N,N’-dicyclohexylcarbodiimide (44 mg, 0.21 mmol,
0.58 equiv.) in CH2 Cl2 (1 mL) was added slowly and the mixture was
stirred for 1 h at 0 °C. The reaction mixture was allowed to warm to
room temperature and stirred for further 16 h. A white precipitate was
ﬁltered oﬀ, and the ﬁltrate was diluted with EtOAc (20 mL), washed with
water (25 mL) and brine (25 mL), dried over MgSO4 , and concentrated
under reduced pressure. The crude product was puriﬁed by column
chromatography using hexane/EtOAc (7:1 to 3:1) as mobile phase to
yield the intermediate 2-allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2yl)phenyl-2-((tert-butyldiphenylsilyl)oxy) acetate as colorless solid (96 mg,
38%). 1 H NMR (400 MHz, acetone-d6 ): 𝛿 = 11.77 (s, 1H), 7.99 (dd, J =
3.0, 6.5 Hz, 1H), 7.76–7.71 (m, 4H), 7.52 (dd, J = 1.8, 7.5 Hz, 1H), 7.50
(d, J = 1.3 Hz, 1H), 7.48 (d, J = 1.4 Hz, 1H), 7.46 (t, J = 1.6 Hz, 1H),
7.44 (t, J = 1.0 Hz, 1H), 7.43 (t, J = 1.1 Hz, 1H), 7.41 (t, J = 1.6 Hz, 1H),
7.38–7.33 (m, 3H), 7.30 (dd, J = 1.8, 7.3 Hz, 1H), 7.28–7.23 (m, 2H), 7.21
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(dd, J = 1.4, 7.4 Hz, 1H), 5.89 (ddt, J = 6.7, 10.1, 16.8 Hz, 1H), 5.07–4.97
(m, 2H), 4.77 (d, J = 9.7 Hz, 2H), 3.27 (dd, J = 1.5, 6.7 Hz, 2H), 1.05 (s,
9H); 13 C NMR (101 MHz, DMSO-d6 ): 𝛿 = 210.07, 169.84, 136.33, 135.43,
132.38, 130.52, 130.01, 129.37, 128.39, 127.57, 127.16, 34.50, 26.88;
HRMS (ESI): m/z 717.2093 calculated for C42 H39 Cl2 N2 O3 Si+ ([M+H]+ ),
found 717.2093.
2-Allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2-yl)phenyl-2-((tertbutyldiphenylsilyl)-oxy) acetate (40 mg, 56 µmol, 1.0 equiv.) was dissolved
in THF (1 mL) and cooled to 0 °C. Glacial acetic acid (65 µL, 1.1 mmol,
20 equiv.) was added and the mixture was stirred for 15 min at 0 °C. Tetran-butylammonium ﬂuoride (1 m solution in THF, 0.15 mL, 0.15 mmol,
2.7 equiv.) was added slowly to the reaction mixture. The mixture was
stirred for 30 min at 0 °C and additional 90 min at room temperature.
The mixture was then quenched with saturated aqueous ammonium
chloride solution (15 mL) and extracted with EtOAc (3 × 15 mL). The
combined organic layers were washed with brine (30 mL), dried over
MgSO4 , ﬁltered and concentrated under reduced pressure. The crude
product was puriﬁed by column chromatography using hexane/EtOAc
(4:1 to 1:1) as mobile phase to yield compound 2 as colorless solid
(22 mg, 82%). mp = 138.7 °C; IR vmax 3546.9, 3061.7, 2922.5, 1741.4,
1465.2, 1191.2, 1064.9, 761.8 cm−1 . UV/vis 𝜆max 210, 225, 235, 270 nm.
1 H NMR (500 MHz, DMSO-d ): 𝛿 = 12.88–12.81 (m, 1H, NH), 7.90 (ddt,
6
J = 1.9, 4.2, 5.8 Hz, 1H, CHar ), 7.53 (d, J = 8.0 Hz, 1H, CHar ), 7.47 (ddd,
J = 1.8, 3.8, 7.4 Hz, 1H, CHar ), 7.40–7.29 (m, 7H, CHar ), 7.29–7.24 (m,
1H, CHar ), 5.97–5.86 (m, 1H, CH2 ═CH), 5.52 (dq, J = 2.0, 4.3 Hz, 1H),
5.13 (dt, J = 2.1, 17.2 Hz, 1H, CH═CH2 ), 5.10–5.05 (m, 1H, CH═CH2 ),
4.41 (dd, J = 3.5, 4.5 Hz, 2H, C(═O)CH2 ), 3.35–3.30 (m, 2H, Car CH2 );
13 C NMR (126 MHz, DMSO-d ) 𝛿 = 171.97, 145.74, 143.00, 137.62,
6
136.43, 134.55, 134.40, 133.30, 132.61, 132.53, 130.65, 130.60, 130.41,
130.22, 129.98, 129.44, 127.57, 127.54, 127.38, 127.31, 126.88, 126.64,
123.65, 117.02, 60.73, 34.53; HRMS (ESI): m/z 479.0924 calculated for
C26 H21 Cl2 N2 O3 + ([M+H]+ ), found 479.0920.
2-Allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2-yl)phenyl
2methoxyacetate (2a): 2-Methoxyacetic acid (13 mg, 0.14 mmol, 1.0
equiv.) was dissolved in CH2 Cl2 (1 mL). 4-(Dimethylamino)pyridine
(1.7 mg, 0.014 mmol, 0.10 equiv.) and 4 (60 mg, 0.14 mmol, 1.0
equiv.) were added; the mixture was cooled to 0 °C, and N,N’dicyclohexylcarbodiimide (44 mg, 0.21 mmol, 1.5 equiv.) was added.
The mixture was stirred for 5 min at 0 °C, then allowed to warm to room
temperature and stirred for 16 h. Formed precipitates were ﬁltered oﬀ,
and the ﬁltrate was concentrated under reduced pressure. The residue
was dissolved in CH2 Cl2 (20 mL) and washed with aqueous hydrochloric
acid solution (0.5 m, 2 × 15 mL) and saturated aqueous NaHCO3 solution
(2 × 15 mL). The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The crude product was puriﬁed by column
chromatography using hexane/EtOAc(10:1 to 3:1) as mobile phase to
yield the title compound as colorless solid (40 mg, 57%). mp = 220.1 °C;
IR vmax 3061.5, 2921.0, 2958.0, 2820.1, 1764.2, 1465.3, 1415.6, 1113.2,
756.8 cm−1 . UV/vis 𝜆max 210, 285 nm. 1 H-NMR (400 MHz, DMSO-d6 ): 𝛿
= 12.90 (s, 1H, NH), 7.91 (dd, J = 7.5, 2.0 Hz, 1H, CHar ), 7.52 (dd, J =
8.0, 1.3 Hz, 1H, CHar ), 7.47–7.26 (m, 9H, 9 × CHar ), 5.90 (ddt, J = 16.7,
10.0, 6.6 Hz, 1H, CH2 ═CH), 5.16–5.03 (m, 2H, CH═CH2 ), 4.37 (s, 2H,
OCH2 ), 3.33 (d, J = 7.6 Hz, 2H, Car CH2 ), 3.13 (s, 3H, CH3 ); 13 C-NMR
(100 MHz, DMSO-d6 ): 𝛿 = 168.9, 145.0, 142.3, 136.0, 134.1, 133.9, 132.9,
132.3, 132.1, 130.2, 130.0, 129.7, 129.4, 129.0, 127.1, 126.8, 126.2, 126.0,
122.9, 116.5, 69.2, 58.2, 34.0; HRMS (ESI): m/z 493.1080 calculated for
C27 H23 Cl2 N2 O3 + ([M+H]+ ), found 493.1085.
2-Allyl-6-(4,5-bis(2-chlorophenyl)-1H-imidazol-2-yl)phenyl Acetate (2b):
Glacial acetic acid (8.6 mg, 0.14 mmol, 1.0 equiv.) was dissolved in CH2 Cl2
(1 mL). 4-(Dimethylamino)pyridine (1.7 mg, 0.014 mmol, 0.1 equiv.) and
4 (60 mg, 0.14 mmol, 1.0 equiv.) were added to the reaction mixture; the
mixture was cooled to 0 °C, and N,N’-dicyclohexylcarbodiimide (44 mg,
0.21 mmol, 1.5 equiv.) was added. The mixture was stirred for 5 min at
0 °C, then allowed to warm to room temperature and stirred for 16 h.
Formed precipitates were ﬁltered oﬀ, and the ﬁltrate was concentrated under reduced pressure. The residue was dissolved in CH2 Cl2 (20 mL) and
washed with aqueous hydrochloric acid solution (0.5 m, 2 × 15 mL) and
saturated aqueous NaHCO3 solution (2 × 15 mL). The organic layer was
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dried over MgSO4 and concentrated under reduced pressure. The crude
product was puriﬁed by column chromatography using hexane/ethyl acetate (10:1 to 3:1) as mobile phase to yield the title compound as colorless solid (35 mg, 53%). mp = 225 °C; 1 H NMR (400 MHz, DMSO-d6 ):
𝛿 = 12.83 (s, 1H, NH), 7.87 (dd, J = 7.3, 2.2 Hz, 1H, CHar ), 7.52 (dd,
J = 7.9, 1.4 Hz, 1H, CHar ), 7.44–7.25 (m, 9H, 9 × CHar ), 5.91 (ddt, J =
16.8, 10.0, 6.7 Hz, 1H, CH2 ═CH), 5.16–5.04 (m, 2H, CH═CH2 ), 3.35–3.29
(m, 2H, Car CH2 ), 2.26 (s, 3H, CH3 ); 13 C-NMR (101 MHz, DMSO-d6 ): 𝛿 =
169.1, 145.7, 142.5, 136.1, 134.2, 133.8, 132.8, 132.1, 132.0, 130.1, 130.0,
129.7, 129.5, 128.9, 127.1, 126.8, 126.3, 126.0, 123.2, 116.4, 34.1, 21.2;
HRMS (ESI): m/z 463.0975 calculated for C26 H21 Cl2 N2 O2 + ([M+H]+ ),
found 463.0976.
4-(4,5-bis(2-Chlorophenyl)-1H-imidazol-2-yl)-2-ethoxyphenol (3): 1,2bis(2-Chlorophenyl)ethane-1,2-dione (5, 0.14 g, 0.50 mmol, 1.0 equiv.),
3-ethoxy-4-hydroxybenzaldehyde (7, 83 mg, 0.50 mmol, 1.0 equiv.), and
ammonium acetate (385 mg, 5.0 mmol, 10 equiv.) were dissolved in
glacial acetic acid (2.5 mL) and heated for 5 min to 180 °C under microwave irradiation. After cooling to room temperature, the mixture was
added dropwise to a cold ammonium hydroxide solution (25%, 50 mL).
The mixture was then extracted with EtOAc (4 × 20 mL); the combined
organic layers were washed with 50% (w/w) aqueous sodium bisulﬁte
solution (6 × 30 mL). The organic layer was dried over MgSO4 and
concentrated under reduced pressure. The crude product was puriﬁed
by column chromatography using CH2 Cl2 with 5% MeOH as mobile
phase to yield the title compound as colorless solid (101 mg, 48%). mp =
215 °C; 1 H-NMR (400 MHz, DMSO-d6 ): 𝛿 = 12.90 (s, 1H, NH), 7.91 (dd,
J = 7.5, 2.0 Hz, 1H, CHar ), 7.52 (dd, J = 8.0, 1.3 Hz, 1H, CHar ), 7.47–7.26
(m, 9H, 9 × CHar ), 5.90 (ddt, 3J = 16.7, 10.0, 6.6 Hz, 1H, CH2═CH),
5.16–5.03 (m, 2H, CH═CH2 ), 4.37 (s, 2H, OCH2 ), 3.33 (d, J = 7.6 Hz,
2H, Car CH2 ), 3.13 (s, 3H, CH3 ); 13 C-NMR (101 MHz, DMSO-d6 ): 𝛿 =
147.1, 146.6, 145.9, 136.5, 134.2, 132.6, 132.1, 132.0, 131.9, 130.7, 129.6,
129.6, 129.5, 129.2, 128.6, 126.9, 126.5, 125.7, 121.6, 118.0, 115.5, 110.2,
63.7, 14.5; HRMS (ESI): m/z 425.0818 calculated for C23 H19 Cl2 N2 O2 +
([M+H]+ ), found 425.0822.
Activity Assays of Isolated COX-1 and COX-2: Puriﬁed ovine oCOX-1
(Cayman Chemicals; 50 units) or human recombinant hCOX-2 (Cayman
Chemicals; 20 units) in 100 mm Tris buﬀer pH 8, 5 mm glutathione, 5 µm
hemoglobin, and 100 µm EDTA were pre-incubated with test compounds
for 5 min at 4 °C followed by 1 min at 37 °C. Then, arachidonic acid (2 µm
for COX-2 and 5 µm for COX-1) was added, and incubations were continued for another 10 min at 37 °C. Formation of COX-derived 12-HHT from
arachidonic acid was analyzed by UV-RP-HPLC.[58]
COX Colorimetric Inhibitor Screening Assay: The peroxidase activity
ovine oCOX that catalyzes the reduction of the endoperoxide PGG2 into
the corresponding alcohol (PGH2 ), which is the precursor of PGs, thromboxane, and prostacyclin, was measured. 10 µL of test compound in
DMSO was added to a solution (180 µL) composed of assay buﬀer (0.1 m
Tris-HCl pH = 8, 160 µL), heme solution (Cayman Chemicals, Ann Arbor,
MI, USA; item number: 760116 [300 µL of hemin in DMSO], 10 µL), and
10 µL of 7.49 U mL−1 oCOX-1 (Cayman item number: 760110) or 8.14 U
mL−1 human hCOX-2 solution (Cayman item number: 760119), respectively. After a 5 min incubation at 25 °C, 20 µL of N,N,N’,N’-tetramethyl-pphenylenediamine (TMPD) solution (Cayman item number: 760117) and
20 µL of arachidonic acid (100 µm) were added, and the incubation was
continued for 5 min at 25 °C. The appearance of oxidized TMPD was monitored by reading the absorbance at l = 590 nm on a Victor 3 instrument
(PerkinElmer, Waltham, MA, USA). According to the manufacturer’s recommendation (Cayman Chemicals), stock solutions were prepared solubilizing the test compounds in DMSO to be then diluted by the same solvent
to obtain the appropriate concentrations. The concentration of DMSO in
the solution was 5.3% before and 4.3% after the addition of 20 µL of TMPD
solution and 20 µL of arachidonic acid.
COX-1 Product Formation in Human Primary Platelets: Human peripheral blood (University Hospital Jena, Germany) was obtained by
venipuncture in heparinized tubes (16 IE heparin per mL of blood) with
informed consent from healthy male and female adult donors (age: 18–
65 years, had done 12 h fasting) that had not taken any anti-inﬂammatory
drugs during the previous 10 days. The registered blood donors were
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physically inspected by a clinician before blood collection. Experimental
protocols using human platelets and monocytes were approved by the
ethical commission of the Friedrich–Schiller-University Jena, Germany.
The blood was centrifuged at 4000 × g for 20 min at 20 °C for preparation
of leukocyte concentrates, which were subjected to dextran sedimentation
and centrifugation on lymphocyte separation medium (LSM 1077, GE
Healthcare, Freiburg, Germany). For isolation of platelets, the supernatants were mixed with phosphate-buﬀered saline (PBS) pH 5.9 (3:2),
centrifuged (2100 × g, 15 min, 20 °C), and the pelleted platelets were
resuspended in PBS pH 5.9/0.9% NaCl (1:1, v/v). Washed platelets were
ﬁnally resuspended in PBS pH 7.4 containing 1 mg mL−1 glucose and
1 mm CaCl2 . Freshly isolated human platelets (108 mL−1 PBS pH 7.4
containing 1 mg mL−1 glucose and 1 mm CaCl2 ) were pre-incubated with
the test compounds for 15 min at 37 °C and stimulated for 10 min at 37 °C
with 5 µm arachidonic acid. COX product formation was stopped after
10 min at 37 °C by addition of 1 mL ice-cold methanol, and the formed
12-HHT was analyzed by UV-RP-HPLC.[59]
Lipid Mediator Proﬁling in Activated Human Primary Monocytes: After
centrifugation of leukocyte concentrates on separation medium, as detailed for the isolation of human platelets, the peripheral blood mononuclear cell fraction was incubated in culture ﬂasks (Greiner) for 1.5 h
at 37 °C and 5% CO2 in RPMI 1640 medium (Sigma–Aldrich, Deisenhofen, Germany) supplemented with fetal calf serum (Sigma–Aldrich;
5%), L-glutamine (Sigma–Aldrich; 2 mm), and penicillin/streptomycin
(GE Healthcare; 100 U mL−1 and 100 µg mL−1 ). Adherent monocytes (2 ×
106 ) were harvested and either directly pre-incubated with vehicle (DMSO)
or test compounds for 10 min or ﬁrst stimulated with LPS (Sigma–Aldrich,
1 µg mL−1 ) for 24 h at 37 °C and 5% CO2 to induce COX-2 expression.
Cells were then activated with 2.5 µm A23187 (Sigma–Aldrich) for 10 min
at 37 °C. Ice-cold methanol was added and lipid mediators were extracted
by solid phase extraction (Sep-Pak Vac 6cc 500 mg 6 mL−1 C18; Waters,
Milford, USA) following protein precipitation at −20 °C and acidiﬁcation
(pH 3.5).[60] d8-5S-HETE, d4-LTB4 , d5-LXA4 , d5-RvD2, d4-PGE2 (200 nm,
each Cayman Chemical), and d8-arachidonic acid (10 µm, Cayman Chemical) were used as internal standards. Eicosanoids, docosanoids, and fatty
acids were separated on an ACQUITY UPLC BEH C18 column (1.7 µm,
2.1 × 100 mm; Waters) using an Acquity Ultraperformance LC system (Waters) and detected by a QTRAP 5500 mass spectrometer (Sciex) equipped
with an electrospray ionization source.[60] Lipid mediators were analyzed
by scheduled multiple reaction monitoring in the negative ion mode. External calibration was used for quantiﬁcation, with six diagnostic fragment
ions and the retention time being conﬁrmed using external standards (Cayman Chemicals).
Reagents for Protein Crystallization: Fe3+ -protoporphyrin IX (heme)
was purchased from Frontier Scientiﬁc (Logan, UT). n-octyl 𝛽-Dglucopyranoside (𝛽-OG) and C10E6 were purchased from Anatrace
(Maumee, OH). EDTA free protease inhibitor was purchased from Roche
Applied Science (Penzberg, Germany). All other chemicals (reagents and
solvents) were purchased from Sigma Life Science (St. Louis, MO, USA).
Protein Expression and Puriﬁcation: The gene encoding ovine COX-1
was cloned in a modiﬁed pFastBac vector (Invitrogen, Waltham, MA, USA)
engineered with an N-terminal 8X-His tag and a Tobacco Etch Virus protease cleavage. Generation of recombinant baculovirus, expression of recombinant his-tagged oCOX-1, and puriﬁcation of untagged oCOX-1 were
carried out as described.[31] Nickel-NTA Agarose beads were purchased
from Gold Biotechnology (St. Louis, MO, USA). Pure oCOX-1was concentrated using a 2 mL Vivaspin concentrator (Sartorius, Göttingen, Germany) to 5–6 mg mL−1 (as assessed by BCA protein assay, Pierce, Rockford, IL) in HEPES pH = 7.0, 40 mm NaCl, and 0.4% 𝛽-OG and used for
crystallization. BCA protein reagent was purchased from Pierce (Thermo
Scientiﬁc, Waltham MA, USA).
Crystallographic Methods: oCOX-1 was reconstituted with a twofold
molar excess of heme (Fe3+ -protoporphyrin IX) and twofold molar excess
of 2a and allowed to incubate at room temperature for 10 min before setting up crystallization trays. Crystallization trays were set up at 25 °C using
the sitting-drop vapor diﬀusion method. 1 µL of protein was mixed with
1 µL of crystallization solution consisting of 0.5–0.9 m LiCl, 0.7 m sodium
citrate pH 6.5, 1 mm sodium azide, and 0.3% (w/v) 𝛽-OG and was equi-
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librated within a reservoir containing 0.5–0.9 m LiCl, 0.7 m sodium citrate pH 6.5, 1mm sodium azide, and 0.3% (w/v) 𝛽-OG. Crystals appeared
within 2–3 weeks. Before data collection, crystals were harvested, brieﬂy
soaked in a solution containing 1 m sodium citrate, 1 m LiCl, 0.15% 𝛽OG, and 1 mm sodium malonate as a cryo-protectant and ﬂash-frozen
in liquid nitrogen. Diﬀraction data were collected at beamline 9–2 at the
Stanford Synchrotron Radiation Lightsource (SSRL, Menlo Park, CA, USA)
using a Dectris PILATUS 6M detector and processed using HKL2000.[61]
The structure was solved by molecular replacement using the program
PHASER and oCOX-1 (PDB 5WBE) as a search model.[62,63] The hexagonal asymmetric unit contains a dimer of oCOX-1 that was subjected to
iterative cycles of reciprocal and real space reﬁnement using distinct TLS
groups as implemented in phenix.reﬁne.[64] The density for 2a was identiﬁed in Fo-Fc polder maps, as implemented in phenix.polder.[65] Visualization and model building were done using Coot.[66] The ﬁnal model
consisted of residues 32–584 of oCOX-1, two Fe3+-protoporphyrin IX, six
carbohydrates, and one compound 2a bound in the oCOX-1 active site of
each monomer (Table S4, Supporting Information). Figures were prepared
with PyMOL (Schrödinger, New York, NY, USA).[67] The binding free energy
(ΔG) was calculated using PISA software[68] and intramolecular contacts
between compound 2a and oCOX-1 were measured using PDBsum.[69]
Preliminary Bioactivity Screening: Initial tests were conducted by
Euroﬁns (Cerep SA, France) on a fee-for-service basis. The assay
protocols can be found on the service provider’s website at www.
euroﬁnsdiscoveryservices.com. Initial screening measurements were conducted with two replicates at 50 µm concentration. IC50 , Ki , and KB values
were determined by the service provider from eight diﬀerent concentrations with two replicates for each concentration. Log(concentration) response curves (four-parameter logistic ﬁt) were plotted in Prism 7 (GraphPad Software, La Jolla, CA, USA). Inhibition constants (Ki ) were calculated
according to the Cheng–Prusoﬀ equation (Ki = IC50 [1+(C/KD )]−1 ), where
C is the concentration of the radioligand in the assay and KD the aﬃnity
of the radioligand for the receptor. Binding constants (KB ) were calculated
with the modiﬁed Cheng–Prussoﬀ equation (KB = IC50 [1+(C/EC50.C )]−1 ),
where C is the concentration of control binder in the assay and EC50.C its
EC50 value. Euroﬁns assay catalogue numbers: COX-1 (4173), EP1 (2054),
EP2 (1957), EP3 (2578), EP4 (1872), CDK1 (2875), CDK2 (2908), CDK4
(2876), SAPK2A (2881), ERK2 (2878), JNK3 (2916), GSK3beta (2879),
IKKalpha (2937), IKKbeta (2938), IKKepsilon (2587), IRAK4 (2933), PKD1
(2204), ROCK2 (2884), CB1 (1744, 1745), CB2 (1746, 1747), CRF1 (505),
CCK2 (1879), GR (469), OX1 (2235), OX2 (2350).
Hybrid Reporter Gene Assays for Nuclear Receptors: The Gal4 hybrid
reporter gene assays of the following nuclear receptors were conducted
as described:[70] peroxisome proliferator-activated receptors 𝛼/𝛾/𝛿 (PPAR
𝛼/𝛾/𝛿), liver X receptors 𝛼/𝛽 (LXR 𝛼/𝛽), retinoic X receptor 𝛼 (RXR𝛼),
retinoic acid receptor 𝛼(RAR𝛼), farnesoid X receptor (FXR), vitamin D
receptor (VDR), constitutive androstane receptor (CAR). pFA-CMV-based
constructs comprising the ligand binding domain of the human nuclear
receptor in question were used as expression plasmids for the chimera
receptors. pFR-Luc (Stratagene, La Jolla, CA, USA) served as reporter
plasmid and pRL-SV40 (Promega, Madison, WI, USA) for normalization
of transfection eﬃciency and cell growth. The assays were conducted
in 96-well format in HEK293T cells. In brief, transient transfection was
carried out using Lipofectamine LTX reagent (Invitrogen) according
to the manufacturer’s protocol. After transfection and incubation with
test compounds (12–14 h), cells were assayed for luciferase activity
using Dual-Glo Luciferase Assay System (Promega) according to the
manufacturer’s protocol. Luminescence was measured with an Inﬁnite
M200 luminometer (Tecan, Männedorf, Switzerland). Normalization of
transfection eﬃciency and cell growth was done by division of ﬁreﬂy
luciferase data by renilla luciferase data and multiplying the value by 1000
resulting in relative light units (RLU). Fold activation was obtained by
dividing the mean RLU of a test compound at a respective concentration
by the mean RLU of untreated control. All hybrid assays were validated
with reference agonists (PPAR𝛼: GW7647; PPAR𝛾: pioglitazone; PPAR𝛿:
L165041; LXR𝛼/𝛽: T0901317; FXR: GW4064; RXR𝛼: bexarotene; RAR𝛼:
tretinoin; VDR: calcitriol; CAR: CITCO) which yielded EC50 values in
agreement with literature. The assays were conducted in duplicates with
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at least two independent repeats and for active compounds repeated
without hybrid receptor coding DNA for every test compound at the
highest tested concentration to exclude unspeciﬁc eﬀects.
Cytotoxicity Study: All cell lines were purchased from American Type
Culture Collection (ATCC; Manassas, VA, USA). Caco-2, MIA PaCa-2, and
MCF7 cells were grown in Dulbecco’s Modiﬁed Eagle’s high glucose
medium, Hep-G2 cells in Minimum Essential Medium, PANC-1 cells in
RPMI-1640 medium, in a humidiﬁed incubator at 37 °C under 5% CO2 atmosphere. Media were supplemented with 10% fetal bovine serum, 2 mm
glutamine, 100 U mL−1 penicillin, and 100 µg mL−1 streptomycin. A-549
cells were grown in HAM-F12 medium containing 10% fetal bovine serum
and 1% penicillin–streptomycin in a humidiﬁed atmosphere at 37 °C. Each
cell line was used from passage 5 to passage 20. Determination of cell
growth was performed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) assay. 20 000 cells per well were seeded
into 96-well plates in a ﬁnal volume of 100 µL, and the various compound
concentrations were added in a volume of 50 µL. Stock solution was prepared just before its use. After 48 h, MTT (10 µL, 0.5 mg mL−1 ) was added
to each well. The supernatant was removed after 3–4 h of incubation at
37 °C. The formazan crystals were allowed to solubilize using 100 µL of
DMSO:EtOH (1:1), and absorbance values (l570 ) were determined on a
Victor 3 (PerkinElmer Life Sciences) microplate reader. The absorbance
of the untreated cells was deﬁned as 100% cell viability; the viability of
cells incubated with drugs was measured in each experimental condition
and expressed as a percentage (%) of viable cells in the deﬁned condition
versus the vitality of the untreated cells. EC50 values were determined by
graphical analysis using GraphPad Prism 8.4.3 (GraphPad Software, La
Jolla, CA).
Statistical Analysis: Bioactivity data are presented as mean ± standard error of the mean (SEM) of a number of n independent experiments.
Outliers were determined using Grubb’s test. Neither were the sample
sizes pre-determined by statistical methods, samples blinded, nor data
conﬁrmed as normally distributed. Diﬀerent groups were compared by repeated measures one-way or two-way ANOVA followed by Tukey HSD post
hoc test or by two-tailed paired student t-test using a two-sided 𝛼 level of
0.05. P values < 0.05 were considered statistically signiﬁcant. Statistics
were calculated and IC50 values determined by graphical analysis using
GraphPad Prism 8.4.3 (GraphPad Software, La Jolla, CA).
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